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Summary 
For many years portal venous diversion has been used 
for the haemodynamic objectives of stopping or preventing 
haemorrhage from oesophageal varices or, less commonly, 
to treat intractable ascites. Since 1963, a new dimension 
has been added to the old operation of portacaval shunt 
by employing this procedure to alter favourably the course 
of three inborn errors of metabolism: glycogen storage 
disease, hyperlipoproteinaemia and alpha-I-antitrypsin 
deficiency. In this chapter we wilUliscuss the results and 
the potential postoperative -risks of portal diversion for 
these new indications, as well as the possible mechanisms 
of benefit. 
MECHANISM OF PORTAL DNERSION EFFECTS 
It has been increasingly appreciated during the last two 
decades that venous blood from the splanchnic viscera 
















in other kinds of arterial or venous blood. 37.41--44.41> The 
main splanchnic venous 'hepatotrophic' factors are almost 
certainly endogenous hormones of which the single most 
important is insulin. Deprivation of the liver of the so-
called hepatotrophic effects of portal blood has been 
noted under several experimental conditions (including 
portacaval shunt) to cause hepatocyte atrophy, deglyco-
genation and fatty infiltration. With electron-microscopic 
studies, relatively specific findings have been disruption 
and reduction of the rough endoplasmic reticulum (RER) 
and diminution of its lining polyribosomes.30·37.42--44.46 
Since RER is the 'factory' of the cell. a consequent 
reduction in many biosynthetic processes would be 
expected. Numerous studies have verified this hypothesis. 
We will comment here upon examples chosen because of 
their clarity or because of their probable or proven clinical 
significance. 
The effect of portal diversion upon hepatic lipid metab-
olism has been unusually well studied. We demonstrated 
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reductions of more than 80% in canine hepatic cholesterol 
and triglyceride synthesis. ~O A similar diminution in chol-
esterol and or lipoprotein synthesis has been confirmed 
In rats. dogs. swine and baboons: this has been reviewed 
elsewhere.·17 Reductions in hepatic lipid wnthesls also 
have been documented in patients treated hy us with 
portacaval shunt for familial hypercholesterolaemla (FH). 
:.11.17 and it has been shown that total body cholesterol 
is greatly reduced. 27 It may be considered proved that 
lipid homeostasis is altered to an extraordinary degree hy 
portacaval shunt. with the reduction in hepatic lipid 
synthesis being the greatest change. 
It has been equally well established that bile acid 
synthesis is greatly reduced by portacaval shunt. 2.27 K~T 
Another synthetic pathway that has been well studied 
after portal diversion is the hepatic urea (Krebs-Henseleit) 
cycle. This has been shown by Reichle el al. to be 
depressed by Eck fistula in rats.''! and dogs:-'2 they also 
demonstrated a reductlon in several of the enzymes 
involved in this metabolic pathway. 
As detailed studies are made of other hepatic synthetic 
or metabolic processes after portacaval shunt. it will not 
be surprising if all follow the same pattern. This possibility 
is supported by many studies summarized elsewhere .. 17 
which have shown that portacaval shunt lowers the activity 
of the hepatic microsomal mixed-function enzyme system. 
Aside from illustrating the principle of a wide-ranging 
decline in hepatic synthesis after portacaval shunt. these 
observations are of potential specific importance because 
the microsomal mixed-function enzyme system. for which 
multiple cytochrome P450 and P448 species serve as 
teTminal oxidases. metabolizes a variety of drugs and 
foreign chemicals as well as endogenous compounds such 
as steroids and fatty acids. The depression of this broad-
ranging enzyme system would relate to many of the 
metabolic effects of portal diversion. 
GLYCOGEN STORAGE DISEASE (GSD) 
Portal diversion was first performed for glycogen storage 
disease almost 26 years ago. 311 The rationale for the 
procedure was then naive by present-day standards. It 
was hoped that by short-circuiting splanchnic venous 
blood around the liver. glucose would be made more 
readily available to peripheral tissues. with relief of the 
hypoglycaemia. and that the liver would be coincidentally 
deglycogenated. Subsequent ammal experiments suggest 
that the consequences of portacaval shunt are far more 
subtle and wide-ranging than this simple view. 
That first patient. who had type III glycogen storage 
disease. is still alive more than 26 years after portacaval 
transposition. The bypassed portal venous blood was 
replaced with blood returning from the inferior vena cava. 
an operation which was first described in animals by Child 
el aL. 5 (Figure 50.1). The transposition was used in order 
to avoid the potential hazards of Eck fistula. It was 
appreciated then. and has been amply confirmed since. 
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Figure 50.1 The operation of portacaval transposition that WIt 
used for the first two patients with glycogen storage disease wbo 
were treated with ponal diverSion. Note that the central ponaI 
vein is revascularized with vena caval blood. From Starzl tt til. 
(1965).-'11 with kind permiSSIOn of the authors and the publisher. 
C.V. Mosby. 
.10 . .17 that most animals. including subhuman primates, 
develop wasting and encephalopathy after portal diver-
sion. but it was not appreciated that humans would be an 
exception to this generalization. 
Our first patient had a remarkablv untroubled conva-
lescence. An inferior vena cavagram almost 10 yean 
postoperatively revealed flow of systemic venous blood 
from the distal vena cava to the liver but with a major 
bypass around the liver through azygous and hemiazyJOUl 
collaterals (Figure 50.2). The degree of azygous bypassiq 
was similar to that observed with a comparable aqioo 
graphic study 3 months after the operation. . 
Two more portacaval transpositions were performedt-
one by Riddel el alY In Riddell's patient. the cavoporlll 
anastomosis clotted45 (Figure 50.3). The other attempt 
cost the life of our second patient: the liver was unable· 
to transmit the re-routed vena caval flow. causing hepalic 
swelling and uncontrollable acidOSIS. This 7-year-old child 
died 2 days later. We39 and Hermann and Men:eJ"6 
subsequently recommended that the simpler procedure of 
portacaval shunt be used. To our knowledge this approlCh . 
has been followed in all later cases. By the sprins of 
19qv~ our own series of patients had reached seven. aDd 
six more had been formally reponed in the literatura 
from other centres. Since then our cases have inc_"~ 
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Figure 50.2 Inferior vena cavagram in March 1973 (9i years postoperatively) in Colorado Patient 1. showing a 
patent caval-portal anastomosis (arrow) under two conditions of dye injection. Significant How through the liver. as 
well as around it bv the azygous and other collaterals. was well seen at fluoroscopy. Ive = distal infenor vena cava; 
LRV = left renal vem: PV = portal vein. From Starzl el al. (1973).4.1 with kind permission of the authors and the 
editor of Annals of Surge,,'. 
(a) (b) 
FiRUft 50.3 Studies of the Bristol case of portacaval transposition. The ongmal operation was on 5 May 1965. and 
the examinatIon depIcted was performed in December 1971 by Dr R.1. Sommerville at the Foothills Hospital. 
Calgary, Alberta. (a) lnfenor vena cava gram shOWing obstruction at the anastomotic site (arrowl. IVC = distal 
mtenor vena cava: LRV = left renal vem. Note the extensIve collaterals VIa the azygous system. (b) Demonstration 
of a patent portacaval anastomosIs (arrow) bv means of a retrograde catheterization. IVC = proxImal interior vena 
cava: PV = portal vein. From Stan! el ai. (l973),4S with kind perrntSSlOn of the authors and the editor of AIIMLr 
of Surgery. 
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Table SO. 1 Patients with glycogen storage disease (GSD) treated by portal diversion. Patients 1 and 2 had portacaval transpositions; 
all others had portacaval shunt. 
Patient Age GSD Date of operation Preoperative symptoms Persistent Survival after 
number (years) type hypoglycaemia shunt 
Hypoglycaemia Acidosis Growth postoperatively 
retardation 
8 III 15 October. 1963 Yes Yes Yes No Alive 
:: 7 I 26 June. 1968 Yes Yes Yes Died 2 days 
3 7 I 2 May. 1972 Yes Yes Yes YesG Alive 
~ 11 I 17 Mav. 1972 Yes Yes Yes No Died 4i yean 
5 10 VI 2 AugUst. 1972 Yes Alive 
() 5 III 7 November. 1972 Yes Yes Yes No Alive 
7 3 III 8 November. 1972 Yes Yes Yes YesG Alive 
S 8 I 13 August. 1973 Yes Yes Yes Yesb Alive 
<) 12 I 14 December. 1973 Yes Yes Yes Yes" Alive 
10 1 I 2 October. 1976 Yes Yes Yes YesG Alive 
"Overmght feedmg via nasogastric tube starting 214 years after portacaval shunt. 
"Underwent orthotopIC liver transplantation on 12 February 1982. and was well 14 months later (see text). 
6-phosphatase deficiency) has been the most common 
indication for treatment. with type III disease (amylo-
1.6-glucosidase deficiency) being a distant second (Table 
50.1). 
Metabolic effects 
After portal diversion. most of the children who had pre-
existing hypoglycaemia did not obtain relief from this 
problem or the relief was not complete. Thus. night 
feedings usually had to be continued. Studies of plasma 
insulin and glucagon in several of these patients have 
revealed changes (Figure 50.4). The flat peripheral insulin 
curves typical of type 1 glycogen disease24 became signifi-
cantly elevated after portacaval shunt. and there were 
smaller increases in glucagon. The glucose tolerance 
curves were very little different before and after operation. 
Liver glycogen concentrations in all those patients who 
were later biopsied were not changed. In spite of this, in 
several of our patients and those reported by others, the 
liver underwent a very obvious reduction in size •. 
measured with liver scan planimetry. Even if ob\lIOtIs .... 
shrinkage did not occur. postoperative biopsies always. 
showed a diminution in individual hepatocyte size similar . 
to that produced in animals by portacaval shunt.4$ 
In contrast to the incomplete relief of hypoglycaemia, 
there was profound and permanent relief of all com-
ponents of the hyperlipidaemia which is a characteristic 
of the type 1 disease (Figure 50.5). Correction of other 
metabolic defects was observed. including abnol1llll 
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Figure SO.4 PIIIIIII 
lOsulin and glucose 
concentrations in 
response to an oral 
glucose tolerance test 
before and after 
portacaval shunt in • 
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(Normal value 130) 
___ e Plasma phosphOlipIds tmg 1l 00 ml) 
(Normal range 192·337) 
ci~re 50.5 Effect of parenteral hvperalimentation 
and end-to-side portacaval shunt on the plasma lipids 
of patient 4. whose diagnosis was type I glycogen 
storage dIsease. Note the rapId and relatively 
complete reversal of all abnormalities. From Stanl et 
al. (1973)."' with kind permISSIon of the authors and 
the editor of Annals of Surgery. 
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bleeding. uric ami elevatlons and abnormal calcium 
metabolism. MfK~ These observations have been confirmed 
hv others. o.9 .2.1 
Growth 
All ten of our patients had growth retardation before 
portacaval shunt. Increases in height. which in most cases 
had virtually ceased. have occurred postoperatively at 
the rates listed in Table 50.2. i.e. approximately 0.5 
em/month. 
Table 50.2 Growth rate and complications after portal diver-






















Died 4i years after shunt. 
Primary pulmonary 
hypertensIon: 
NH, = R5 11g1100 ml: 
macroadenomatosts 
Renal artery stenosis 
surgIcally corrected 32 
months after shunt 
Macroadenomatosis. Liver 
transplantation after 81 years 
Renal stone 2 months after 
shunt. Mild artenal 
hypertensIon: 
macroadenomatosis 
Growth cessation after 2 
years 
Quantitative measures of growth were obtained with 
radiographic techniques. 4 :'1 An example of the results is 
shown in Figure 50.6. Comparison of the wrist and hands 
in this 7-year-old stunted child before and 11 t months 
after operation showed the phenomenal effects of bone-
age doubling. In addition to the size change. mineraliz-
ation occurred. as did the appearance of new wrist bones. 
Circulating somatotrophin in these patients was normal. 
The growth spurts may have been at least partially 
attributable to the increased insulin distribution to the 
periphery mentioned earlier (see Figure 50.4) since. in 
recent years. insulin has been recognized to be a major 
growth hormone. comparable in potency to somatotro-
phin. The simpler possibility that better nutrition was 
responsible must also be considered. 
Encephalopathy and other "slcs 
A patient who exhibited hepatic encephalopathy 8 years 
after end-to-side portacaval shunt for type I glycogen 
storage disease also developed multiple filling defects in 
her enlarged liver. The diseased liver was replaced at 
transplantation. and all of the metabolic abnormalities of 
type I GSD were completely relieved. 26 From the study 
of more than half-a-dozen liver-based inborn errors of 
metabolism it has been shown that the phenotype of the 
transplanted organ permanently retains its original donor 
specificity.0I7 
One other child developed a blood ammonia concen-
tration of 85 ILgilOO ml (normal <60 ILgilOO ml for that 
laboratory). but there were no symptoms of encephalo-
pathy. This patient died almost 5 years after ponacaval 
shunt during an attempt at transcaval radiognphic vis-
ualization of the ponacaval anastomosis. Except for 
the slightly elevated blood ammonia concentration. her 
standard liver functlons were normal. At autopsy the liver 
had macroadenomatosis very similar to that in the child 
who underwent liver transplantation. An autopsy finding 
that had not been suspected in life was advaoc:ed right 
ventricular hype, trophy and dilatation. The smaller 
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pulmonary artenes and arterioles had medial muscle 
hypertrophy. medial and intimal fibrosis. scattered 
fibrinoid necrosIs. and numerous plexiform lesions. Such 
cardiopulmonary complications have been documented in 
other patients with type 1 GSD and other liver diseases.:: 
This complication did not have an obvious relationship 
to the portacaval shunt. The macroadenomatosis seen in 
these patients is very common in patients with type 1 
GSD. and was recently reported in seven out of eight 
non-shunted patients aged 3 to 28 years. 1'1 
The present status of portal diversion 
Portacaval shunt in the treatment of glycogen storage 
disease has been supplanted by the continuous night 
feeding schedule advocated by Green el aDK~ and Crigler 
and Folkman. 7 We have not performed a portacaval shunt 
smce October 1976. Our present view is that patients who 
are unmanageable with conservative means should be 
considered candidates for the curative procedure of liver 
transplantation rather than for portal diversion. 
FAMILIAL HYPERCHOLESTEROLAEMIA (FH) 
In March 1973. a 12-year-old girl with homozygous familial 
hyperchoiesterolaemia (FH) was treated with an end-to-
side portacaval shunt: her serum cholesterol concentration 
fell markedly4" (Figure 50.7). In patients with this disease 
there is an absence or deficiency of cell membrane 
lipoprotem receptors l2 .1J and thus a 'switch-off mechan-
ism to control lipid (especially cholesterol) synthesIs is 
not present. 
By March 1982. we had treated 12 patients with FH in 
this wayK~x Eight of the patients were children. aged 
between 2 and 14 years. The four adults were aged 2l. 
31. 37 and 52 years. All but two were homozygous 
for the FH abnormality. Low-density lipoprotein (LOLl 
receptors were looked for by Goldstein and Brown 12. 1.1 
T.E. Starzl. K.A. Porter & S. lwaauld 
ci~re 50.6 The 
dramatic wrist and hand 
bone growth and 
mineralization in patient 
:; with type I GSD in 
the hrst II! 
postoperative months. 
The bracket on the left 
index hnger is 5 em in 
length. From Stanl tl aI. 
(1973). ~~ with kind 
permission of the 
authors and the editor of 
Annals of Surgtry. 
on cultured fibroblasts obtained from all patients and 
many of their close relatives. Nine out of the ten patients 
with homozygous disease were LDL-receptor negative 
and the other was receptor defective. Two of the patients 
had heterozygous disease. 
Effect upon serum lipids 
Total serum cholesterol concentrations fell significantly 
in every patient (Figure 50.7) after portacaval shunt.4I 
The total cholesterol declines ranged from 20 to 55.4% 
(average 33.8%) and were maintained throughout the 
period of study. When measured. LDL cholesterols were 
reduced commensurately. HDL cholesterol and triglycer-
ide levels were variably effected. Tendinocutaneous xan-
thomas regressed or disappeared in every patient (Figure 
50.8) simultaneously with the fall in cholesterol concen-
tration. 
Experience of others In treating FH 
The consistency of the anticholesterolaemic response was 
greater than that noted by other authors. who have 
Portacaval shunt 
Davs Months 
FipR SO.7 Serum cholesterol concentrations after ponac:avll .. 
shunt In patient 1 of our FH series. -
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Ib) 
ci~re SO.8 The hands of patient 1 of the hyperlipidaemia 
,enes: (a) two weeks before: and (b) 16 months after portacaval 
,hunt. 
reported a total of 26 additional patientsK~ of whom 13 
were treated in Johannesburg. IU .51 
In the 13 patients treated elsewnere than Johannesburg 
i ~ummarized 10 Starzl el al.''''). serum cholesterol 
reductions of at least 30% were obtained in ten at the 
'>ame time as tendinocutaneous xanthomas regressed. In 
IWO of the three exceptional patients. shunt thrombosIs 
was proved and in one of these the cholesterol fell by 
~fF% after a later mesocaval shun!." In the third patient. 
reported by Soutar el al . . '" there was presumptlve but 
not definitive evidence of shunt occlUSion. An early 
cholesterol fall of 40% returned several months later to 
nearly preoperative values. At the same time. initially 
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elevated serum glucagon levels. which are typically found 
with a patent shunt. fell to base line. 
Morbidity 
The invariable and long-lasting lipid lowering in our 12 
patients was achieved without surgical morbidity. The 
phYSical development of those children who were normal 
before operation has proceeded. and the growth of those 
who were stunted before has moved towards normal. 
Emotional or intellectual deterioration secondary to the 
portal diversion has not occurred. although one child had 
an acute episode of encephalopathy. which was managed 
with diet. *" 
Effect upon ClIrdlovascular disease 
Patients with homozygous FH usually die of hean disease 
before the age of 20 years. The degree to which the 
cardiovascular complicatlons of FH can be relieved or 
prevented by portal diversion has not been established. 
Reversal of aortic stenosis was seen in two of our patients. 
but regressIOn of atheroma in the coronary aneries 
and aorta was not regularly accomplished:'11 Small and 
phipleyK1~ have examined the factors which could preclude 
the reversal of atheroscleroSIS: some of these. including 
secondary fibrosis. would not be corrected completely by 
the resorption of intravascular xanthomas. Farriaux tl a/.K 
have suggested that anatomical stabilization of the vascular 
disease may be the best that can be hoped for with 
portacaval shunt. even in patients whose angina pectoris 
is relieved. Expenence in several patients from our centre 
and elsewhereD!RK-1hK~g has shown the value of aggressive 
surgical correction of technically remedial cardiovascular 
lesions in combination with portal diversion. Of greater 
importance will be the implementation of aggressive 
therapy at a young age. before the development of 
irreversible cardiovascular complications. In patients with 
FH who are refractory to therapy with diet and medi-
cations. portacaval shunt may be the treatment of choice. 
Postoperatively. conservative treatment should be tried 
again because funher drops in post-shunt cholesterol 
levels have been seen using diet and medications which 
were previously ineffective. 
The staged combination of portacaval shunt and the 
ileal bypass procedure of Buchwald el al." has been tested 
in three patients. with an apparently additive effect lO•28 
in spite of the fact that ileal bypass alone has little or no 
effect In homozygous FH." In dogs. Guzman tl al.'s have 
noted an additive effect of portal diversion by ponacaval 
transposition plus Ileal resection. Efforts by USS2 to docu-
ment a complementary effect of ileal resection and porta-
caval shunt 10 dogs failed to conrirm the claims of Guzman 
el al .• D~ and a subsequent report by Rucker tl al.).& from 
the Minnesota studv has shown that the additive effect 
originally reponed by Guzman tl a/. ls was not sustained. 
13-42 
Umltatlons of portaCIWIII shunt 
Portacaval shunt. with or without supplementary treal-
ment. provides only palliation for patients with FH. The 
amelioration of the abnormal metabolic patterns of FH has 
derived from the countervailing and potentially dangerous 
hepatic abnormalities caused by ponacaval shunt:'K The 
palliatIOn is incomplete. SInce restoration of normal serum 
cholesterol values has not been achieved in any patient 
with homozygous disease. In contrast. the metabolic 
abnormalities of FH can be rectified nearly completely 
hy the ultimate step of liver transplantation. ~ff It has been 
demonstrated that the transplanted liver can provide the 
low-density-lipoprotein binding sites which are absent. or 
underrepresented in the native liver.·' The striking benefit 
of liver transplantation has been confirmed by several 
authors. 17.29 
ALPHA·j·ANTlTRYPSIN DmCIENCY 
(see Chapter 43) 
Patients with this disorder have a low level of plasma 
alpha-I-antitrypsIn (an a-globulin). and a high incidence 
of pulmonary complications. ~ I In 1969. a variable associ-
ation of the alpha-I-antitrypsin deficiency with liver dis-
ease was reported. an observation that has had over-
whelming confirmation. 
The basis for the liver injury may be the hepatic 
production of an abnormal alpha- I -antitrypsin which can-
not be effectively transported out of the liver cells 
and which consequently becomes sequestered within the 
hepatocytes near the rough endoplasmic reticulum. IX 
Irritallon by the entrapped glycoprotein has been the 
postulated cause of the hepatic cirrhosis. portal hyperten-
sion and hepallc failure that follow. The progressive and 
inexorable course that this pathogenesis implies may have 
discouraged attempts to treat complications of the portal 
hypenension (such as variceal haemorrhage) with portal-
svstemlc shunts. 
Between 1976 and 1979. we performed end-to-side 
portacaval shunt in three children with the cirrhotic liver 
disease of alpha-i-antitrypsin deficiency. 4'1 The first two 
patients had had major haemorrhages from oesophageal 
vances. The third had ascites. but the principal reason 
for operation was the hope of influencing the metabolism 
of the alpha-i-antitrypsin. 
Follow-up at 3L 5 and nearly 7 years was reported. 44 
Standard liver function tests have not changed greatly 
SInce the ponacaval shunt (Table 50.3). The serum 
ammoma rose after portacaval shunt in all three patients. 
and the aminotransferase and alkaline phosphatase levels 
fell. The same pattern has persisted for a decade or longer 
In the first and third patients. neither of whom has 
practised any dietary restriction. All liver functions of 
patient 2 were abnormal at the time of ponacaval shunt 
tn March 1978. These tests worsened immediately after-
wards. but then became stable for more than 9t years. 
~ T.E. Sarzl. KA. Porter & S. IwaauId =-
~ 
Subsequent hepatic deterioration which necessitated a 
liver transplantation was sudden. developing over 3-4 
weeks. The low serum alpha-i-antitrypsin levels were not 
appreciably different before and long after the portacaval 
shunts (Table 50.3). 
After portacaval shunt. all three patients had stabiliz-
ation of a previously deteriorating clinical state. However, 
the most objective evidence that the natural history 
of the disease was favourably altered came from the 
histopathological studies of operative and postoperative 
biopsies. All 3 patients had macronodular cirrhosis at the 
time of the portacaval shunt with biopsy findings typical 
of the liver disease of alpha-I-antitrypsin deficiency. Two 
livers were biopsied at the time of portacaval shunt and 
later postoperatively. Both livers remained cirrhotic and 
the cytoplasm of some of the hepatocytes contained 
granules of alpha-I-antitrypsin. Most of the granules were 
small and the number per cell varied greatly~ they were 
commoner at the periphery of the pseudolobules. 
Serial biopsies were obtained in patients 2 and 3. When 
compared with the liver biopsies that had been obtained 
at the time of portacaval shunt. the severity of the cirrhosis 
appeared unaltered. but in patient :2 there was severe 
intrahepatic cholestasis which had not been present 
before. In both patients. the hepatocytes were approxi-
mately 20% smaller than when the portacaval shunt was 
performed. The percentage of hepatocytes containing 
alpha-I-antitrypsin also was lower. In the liver of patient 
2, which was removed at transplantation 9. years after 
portacaval shunt. it was 19.3% (compared to 38.2% in 
the pre-shunt biopsy and 28.5% in a biopsy taken 9 
months later). In patient 3. the percentage 81 years after 
portacaval shunt was 19.05% (compared with 44.5% in 
the pre-shunt biopsy. 48.2% 7 months after portacaval 
shunt. 38.7% at 13 months and 20.4% at 2 years 11 
months). 
The explanation that has been advanced to explain the 
beneficial effect was that the portacaval shunt selectively 
damaged the rough endoplasmic reticulum where the 
synthetic processes of the liver are concentrated. without 
a commensurate reduction in excretorv functions of the 
hepatocytes. 4 '1 The hypothesis of a more favorable equilib-
rium between deposition of the alpha-globulin and its 
elimination has been strengthened by the further passage 
of time. Histopathologically. the reduction in the size of 
the hepatocytes and in the percentage of hepatocytes 
containing alpha-I-antitrypsin granules noted in the earlier 
biopsies has been maintained throughout a decade. 
PORTAL DNERSION VERSUS TRANSPLANTAnON 
In some infants or children. ponacaval shunt could 
be envisaged as a temporIZing step whereby definitive 
treatment with transplantation could be put off for many 
years and perhaps permanently. A ppropriale case selec-
tion will be a problem. Candidates should be those lib 
the three patients in our series who have deveJoped serioaI 
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Table SO.3 Chemistries before end-to-side portacaval shunt and U~ to 12 years later. 
:-lormal Patient 1 Patient 2 Patient 3 
Age In years at testing 
.p 16} 6.!. 16" 1.1.. 9~ 
1 J I ~ J 
Serum bilirubin E~mol/lF <20 26 17 31 ,u) <20 25 
Serum ammonia E~molllF <40 59 116 29-53 95 <40 75 
Serum aspartate aminotransferase <50 150 32 200 101 200 102 
(fUIl)b 
300 61 150 52 Serum alanine aminotransferase <50 260 51 
( lUll) 
117 550 351 Alkaline phosphatase (lUll) <200 1800 595 1 ()()() 
Prothrombin time (seconds) II to 11.5 12 12.8 13 15 11.5 12 
Serum alpha-I-antitrypsin (gil) >2.0 0.3 0.5 0.16 <0.20 0.30 0.22 
Serum protein (gil) >65 63 56 52 52 60 55 
Serum albumin (gil) >30 33 35 35 2M 30 28 
"These tests were In early October 1987. I month before liver transplantation on 3 November. Liver functions detenorated rapidly 
dunng the next few weeks. necessitating transplantation. 
"IV = International Units 
complications of liver disease but in whom reasonable liver 
function and hepatic mass remain. Many such patients 
are now being followed in hepatology and liver transplant 
clinics as candidates for elective liver transplantation. 
The advantage of achieving palliation without transplan-
tation. thereby avoiding the need for chronic immuno-
suppression. is obvious. It is by no means clear that 
portacaval shunting will be the best option in the long 
term. even if it is successful. The shunt operation has no 
effect on the protein inhibitor deficiency. whereas liver 
transplantation restores serum alpha-i-antitrypsIn to nor-
mal. IX The principal physiological function of alpha-I-
antitrypsin is to inhibit neutrophil elastase. I The destruc-
tIon of alveolar walls with consequent emphysema in 
patients with alpha-I-antitrypsin deficiency;!U presumably 
results from the unchecked activity of neutrophil elastase. 
A favourable effect on the lung disease is expected from 
liver transplantation. although with a maximum follow-
up of only 14 years post-transplantation. it is too soon to 
be sure. 
SUMMARY 
Complete portacaval shunt was used to treat ten patients 
with glycogen storage disease (OSD). A favourable effect 
was noted on body growth and a number of metabolic 
abnormalities. More recently. continuous night feedings 
with an intermittently-placed gastric tube or through a 
gastrostomy have been shown to be helpful either before 
or after portacaval shunts. Such alimentation techniques 
have eliminated the need for shunts in almost all patients 
with GSD. Patients who are refractory to such manage-
ment are candidates for liver transplantation. 
Portacaval shunt was perfonned in ten patients with 
homozygous and two with heterozygous familial hypercho-
lesterolaemia (FH). Total serum cholesterol was lowered 
by between 20 and 55.4% during follow-up periods of 7 
to almost 15 years. with commensurate decreases in 
LDL cholesterol. The effect on HDL cholesterol and 
triglyceride levels was variable. Tendinocutaneous xan-
thomas diminished or disappeared. Growth and develop-
ment in children proceeded or accelerated. There was no 
detectable emotional or intellectual deterioration. Hepatic 
failure did not occur. although blood ammonia concen-
trations and serum alkaline phosphatase levels increased 
relative to preoperative values. Cardiac symptoms were 
often improved. but evidence of reversal of cardiovascular 
lesions was inconclusive. Three patients with pre-existing 
heart disease died of cardiac complications after 4. 1U~ 
and 30 months. Although portacaval shunt has been 
effective therapy for patients with FH who were intolerant 
of medical treatment. liver transplantation is a better 
treatment for refractory patients. 
Three paediatric patients with the liver disease of alpha-
I-antitrypsin deficiency and with complications of portal 
hypertension had end-to-side portacaval shunts. Their 
clinical courses were stabilized for up to 12 years. Postop-
erative liver biopsies of two of the patients showed 
the typical histopathological changes caused by portal 
diversion. as well as an apparent reduction in the quantity 
of alpha-I-antitrypsin particles in the hepatocytes. The 
metabolic changes caused by portal diversion have appar-
ently created a more favourable equilibrium between 
the synthesis and excretion of the abnormal alpha-I-
antitrypsin. 
Most patients with serious liver disease caused by 
alpha-I-antitrypsin deficiency are best treated by liver 
transplantation. However. a selected few may have good 
palliation from portacaval shunt. 
13+4 T.E. Starzl. K.A. Porter & S. lwaaulci 
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